
# **U** NOVARTIS

# Dry Eye disease

Dry Eye Disease (DED) is a lack of quality lubrication that can lead to an inflammatory cycle of the ocular surface.<sup>1,2</sup>



#### Multifactorial disease 2,3

- Involves a range of ocular structures:
  - Ocular surface (cornea, conjunctiva, accessory lacrimal glands)
  - Meibomian glands
  - Innervation between the ocular surface and meibomian glands

#### Epidemiology

- Prevalence data varies but as many as 5-50% of people could be affected globally<sup>4</sup>
- Risk factors include age, gender, nutrition, genetic background, disease history and high use of digital screens<sup>3,4</sup>
- Annual cost to US health system is estimated to be US \$3.84 billion<sup>4</sup>

#### Symptoms and disease burden <sup>3</sup>

• Tear film instability

- Ocular discomfort including redness, burning, and stinging
- Visual disturbance
- Potential damage to the ocular surface
- Poorer quality of life (impaired ability to perform day-to-day tasks)

### Unmet medical needs

- Over-the-counter eye drops, the standard of care for DED, often have limited success in moderate-tosevere DED<sup>3,5</sup>
- Many DED products have short duration of effect, delayed onset of action and poor patient tolerability<sup>6</sup>
- Many treatments do not effectively address the signs, symptoms, and underlying pathogenic mechanisms of DED<sup>7</sup>

# References

- 1. Baudouin C, et al. Br J Ophthalmol. 2016; 100:300306;
- 2. Craig JP, et al. Ocul Surf. 2017;15(3):276-283;
- 3. Messmer EM. Dtsch Arztebl Int. 2015;112(5):71-82;
- 4. Stapleton F, et al. Ocul Surf. 2017;15(3):334-365;
- 5. Kim M, et al. BMJ Open Ophthalmol. 2021; 6: e000697;
- 6. Shen Lee B, et al. Clin Ophthalmol. 2020; 14:119-126;
- 7. Aragona P, et al. Br J Ophthalmol. 2021;105(4):446-453.

**Source URL:** *https://prod1.novartis.com/diseases/dry-eye-disease* 

# List of links present in page

1. https://prod1.novartis.com/diseases/dry-eye-disease